应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
00013 和黄医药
休市中 10-09 16:08:08
21.740
+0.160
+0.74%
最高
21.820
最低
21.120
成交量
219.99万
今开
21.620
昨收
21.580
日振幅
3.24%
总市值
189.57亿
流通市值
189.57亿
总股本
8.72亿
成交额
4,735万
换手率
0.25%
流通股本
8.72亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
【券商聚焦】中泰国际:多家药企将公布重要数据 推荐创新药与CXO龙头
金吾财讯 · 10-09 08:38
【券商聚焦】中泰国际:多家药企将公布重要数据 推荐创新药与CXO龙头
交银国际:10月研选配置兼顾防御与收益 看好英伟达(NVDA.US)协鑫科技(03800)中国太平(00966)等
智通财经 · 10-05
交银国际:10月研选配置兼顾防御与收益 看好英伟达(NVDA.US)协鑫科技(03800)中国太平(00966)等
和黄医药公布9月股份变动月报表,股本维持不变
公告速递 · 10-02
和黄医药公布9月股份变动月报表,股本维持不变
和黄医药(00013):从跟随板块到跑赢板块,基本面确认后何时开启新一轮行情?
智通财经 · 10-01
和黄医药(00013):从跟随板块到跑赢板块,基本面确认后何时开启新一轮行情?
利弗莫尔中概股龙头指数盘初微涨
每日经济新闻 · 09-30
利弗莫尔中概股龙头指数盘初微涨
港股异动 | 和黄医药(00013)涨超3% 宣布向FDA提交沃瑞沙®联合泰瑞沙®联合疗法的新药上市申请
智通财经 · 09-30
港股异动 | 和黄医药(00013)涨超3% 宣布向FDA提交沃瑞沙®联合泰瑞沙®联合疗法的新药上市申请
和黄医药(00013)携手阿斯利康向FDA递交沃瑞沙®/泰瑞沙®联合疗法NDA
公告速递 · 09-29
和黄医药(00013)携手阿斯利康向FDA递交沃瑞沙®/泰瑞沙®联合疗法NDA
和黄医药(00013)宣布提交沃瑞沙® (ORPATHYS®) 联合泰瑞沙® (TAGRISSO®) 用于治疗MET驱动的EGFR突变肺癌的美国新药上市申请
智通财经 · 09-29
和黄医药(00013)宣布提交沃瑞沙® (ORPATHYS®) 联合泰瑞沙® (TAGRISSO®) 用于治疗MET驱动的EGFR突变肺癌的美国新药上市申请
和黄医药(00013.HK):将于2026年欧洲肿瘤内科学会 (ESMO) 年会公布数项研究临床数据
智通财经 · 09-24
和黄医药(00013.HK):将于2026年欧洲肿瘤内科学会 (ESMO) 年会公布数项研究临床数据
3年赚了40多亿的和黄医药,李嘉诚才不肯卖
蓝鲸财经 · 09-22
3年赚了40多亿的和黄医药,李嘉诚才不肯卖
港股异动 | 和黄医药(00013)尾盘涨超3% ATTC授权GSK 机构指公司出海路径清晰
智通财经 · 09-17
港股异动 | 和黄医药(00013)尾盘涨超3% ATTC授权GSK 机构指公司出海路径清晰
中金:维持和黄医药(00013)“跑赢行业”评级 目标价升至28港元
智通财经 · 09-08
中金:维持和黄医药(00013)“跑赢行业”评级 目标价升至28港元
一个还没进临床的分子,凭什么卖出12.95亿美元
蓝鲸财经 · 09-07
一个还没进临床的分子,凭什么卖出12.95亿美元
总额可达12.95亿美元,和黄医药BD落地,管理层回应市场疑虑:借助合作加速开发,但不会调整整体战略
每日经济新闻 · 09-04
总额可达12.95亿美元,和黄医药BD落地,管理层回应市场疑虑:借助合作加速开发,但不会调整整体战略
花旗:上调和黄医药(00013)目标价至39港元 维持“买入/高风险”评级
智通财经 · 09-04
花旗:上调和黄医药(00013)目标价至39港元 维持“买入/高风险”评级
大行评级丨里昂:维持和黄医药“跑赢大市”评级,ATTC平台获跨国药企认可
格隆汇 · 09-04
大行评级丨里昂:维持和黄医药“跑赢大市”评级,ATTC平台获跨国药企认可
大行评级丨大和:上调和黄医药目标价至28.5港元,评级一举升至“买入”
格隆汇 · 09-04
大行评级丨大和:上调和黄医药目标价至28.5港元,评级一举升至“买入”
港股异动 | 和黄医药(00013.HK)再涨超6% 与GSK达成12.95亿美元合作 ATTC平台全球价值得到验证
智通财经 · 09-04
港股异动 | 和黄医药(00013.HK)再涨超6% 与GSK达成12.95亿美元合作 ATTC平台全球价值得到验证
异动解读|和黄医药盘中上涨5.3%,与葛兰素史克达成最高12.95亿美元授权合作提振延续
行情直击 · 09-04
异动解读|和黄医药盘中上涨5.3%,与葛兰素史克达成最高12.95亿美元授权合作提振延续
【券商聚焦】交银国际:医药行业收入稳健增长 多重利好推动盈利表现显著改善
金吾财讯 · 09-04
【券商聚焦】交银国际:医药行业收入稳健增长 多重利好推动盈利表现显著改善
加载更多
公司概况
公司名称:
和黄医药
所属市场:
SEHK
上市日期:
--
主营业务:
和黄医药(中国)有限公司是一间主要从事制造及销售药物的投资控股公司。该公司主要通过两个分部运营业务。肿瘤免疫业务分部从事发现、开发和商业化用于治疗癌症和免疫性疾病的靶向疗法和免疫疗法。其中研发包括涵盖药物发现、开发、生产及监管职能的研发活动,上市产品包括通过研发活动开发的药物的已开具发票的销售、推广、生产及分销。其他业务分部从事其他商业化业务,包括其他处方药物及保健品的销售、推广、生产及分销。
发行价格:
--
{"stockData":{"symbol":"00013","market":"HK","secType":"STK","nameCN":"和黄医药","latestPrice":21.74,"timestamp":1791533288000,"preClose":21.58,"halted":0,"volume":2199914,"delay":0,"changeRate":0.007414272474513445,"floatShares":872000000,"shares":872000000,"eps":4.081176322853062,"marketStatus":"休市中","change":0.16,"latestTime":"10-09 16:08:08","open":21.62,"high":21.82,"low":21.12,"amount":47353879,"amplitude":0.032437,"askPrice":21.74,"askSize":4000,"bidPrice":21.72,"bidSize":1000,"shortable":3,"etf":0,"ttmEps":0.15845982388120616,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1791768600000},"marketStatusCode":7,"adr":0,"listingDate":1624982400000,"exchange":"SEHK","adjPreClose":21.58,"openAndCloseTimeList":[[1791509400000,1791518400000],[1791522000000,1791532800000]],"volumeRatio":1.1024927332257821,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/00013","defaultTab":"news","newsList":[{"id":"2674892318","title":"【券商聚焦】中泰国际:多家药企将公布重要数据 推荐创新药与CXO龙头","url":"https://stock-news.laohu8.com/highlight/detail?id=2674892318","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674892318?lang=zh_cn&edition=full","pubTime":"2026-10-09 08:38","pubTimestamp":1791506310,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中泰国际表示,多家创新药企业将于10月下旬ESMO公布重要临床数据。ESMO是欧洲最具盛名和影响力的肿瘤学会议,LBA是最高级别的研究成果展示,因此ESMO公布的LBA在医药行业广受关注。中国企业入选的LBA中,有四项入选最高级别的主席研讨会。该机构认为,以上情况表明中国创新药研发能力在海外广受认可,因此创新药板块值得继续关注。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250109/MjdmY2Y4OTEwODUyNTc5NjI3Mg==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MjdmY2Y4OTEwODUyNTc5NjI3Mg==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1993342","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["WX","01177","09926","LU2097828557.USD","LU0348827113.USD","06160","LU1831875114.USD","LU2488822045.USD","MEDX","LU2399975544.HKD","LU0307460666.USD","LU0314109678.HKD","LU0708995153.HKD","LU1008478684.HKD","06978","159992","LU2125910500.SGD","IBBQ","LU1688375341.USD","02269","06821","LU0823426308.USD","BK1521","LU1960683339.HKD","LU2097828714.EUR","LU0149534421.HKD","LU0327786744.USD","LU0067412154.USD","LU0561508036.HKD","IE00BZ08YR35.GBP","KCE","BK1191","KURE","IE0008369823.USD","IE00B5MMRT66.SGD","LU0029874905.USD","02359","SG9999002463.SGD","00013","LU0320764599.SGD","02268","LU0572944931.SGD","LU0348767384.USD","01093","LU0348783233.USD","LNGR","LU1242518931.SGD","01801","CXO","BK1500"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673398706","title":"交银国际:10月研选配置兼顾防御与收益 看好英伟达(NVDA.US)协鑫科技(03800)中国太平(00966)等","url":"https://stock-news.laohu8.com/highlight/detail?id=2673398706","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673398706?lang=zh_cn&edition=full","pubTime":"2026-10-05 17:10","pubTimestamp":1791191454,"startTime":"0","endTime":"0","summary":"该行公布10月研选,包括英伟达,看好长期AI需求的可持续性;敏实集团,传统业务保持韧性,新业务进入放量期;腾讯,市场再次重视agent的商业化进度;和黄医药,重返增长通道,赛沃替尼、ATTC迎关键突破;协鑫科技,行业大幅减产有望推动多晶硅价格进一步上涨;中国太平,看好高股息与估值修复潜力。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1503650.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1515016050.SGD","LU0449509016.USD","LU1785774172.SGD","LU0918141705.HKD","07388","LU0169518387.USD","LU0293314216.USD","SG9999006597.SGD","LU0608807946.USD","SG9999014567.USD","NVDS","LU1988902786.USD","LU0797268264.HKD","LU1815336760.USD","LU0053666078.USD","LU0898667661.SGD","LU0463099449.HKD","LU0342679015.USD","LU2860962120.EUR","LU0979878070.USD","LU0210533765.USD","LU2272731782.SGD","EFIV","00700","LU1633808545.USD","SG9999001069.SGD","XSOE","LU0154236417.USD","LU0557290698.USD","LU0828238088.HKD","LU2250418816.HKD","LU2271345857.HKD","LU0109391861.USD","LU1116320901.HKD","LU2476274720.SGD","LU0061475181.USD","LU2462157665.USD","LU0795875086.SGD","LU2360106780.USD","LU0348825331.USD","LU0188438112.USD","LU1202635105.USD","LU0819121731.USD","NVDD","LU2462611646.USD","LU0164880469.USD","LU1880383440.USD","BK1609","LU0543330483.HKD","LU2089283258.USD","LU0354030438.USD","LU1923622291.USD","LU1303224171.USD","NVYY","GB00BDT5M118.USD","LU0531970944.HKD","LU0651947912.USD","LU0210536198.USD","LU2226246903.HKD","SGXZ31699556.SGD","LU0157215616.USD","LU0214875030.USD","LU0431992006.USD","LU0972618739.USD","SMH","LU1720051017.SGD","LU2045819591.USD","GAMR","FTEC","LU1064131342.USD","IE00BJLML261.HKD","LU2491050071.SGD","HK0000306685.HKD","LU0640798160.USD","LU1934455194.USD","LU0494093205.USD","LU1048596156.SGD","LU1282648689.USD","IE0004086264.USD","LU1366334578.USD","LU1242518931.SGD","LU2505996509.AUD","IE00B4YYXB79.USD","LU2294711713.HKD","IE00B067MR52.USD","LU2249611893.SGD","LU1951200564.SGD","BK1521","LU1102505929.USD","LU2286300806.USD","LU1116320737.USD","SG9999001846.SGD","SG9999003461.SGD","LU2471134523.USD","NVD2.UK","LU1235295612.USD","LU0395794307.EUR","LU0051755006.USD","LU1051768304.USD","LU1282649810.SGD","LU2403377893.USD","LU2506951792.HKD","LU0823434583.USD","IE0003795394.USD","SG9999006514.SGD","IETC","IE00BDRTCR15.USD","LU0158827948.USD","LU0106259558.USD","IE0034235303.USD","LU0327786744.USD","LU1051769294.HKD","IE0034235188.USD","LU0210528500.USD","LU0444973449.USD","LU0328353924.USD","LU0861579265.USD","IE0034235295.USD","LU0648948544.HKD","LU1226287529.USD","LU0192582467.USD","SG9999014542.SGD","LU1821325948.USD","EMCS","LU1282649141.HKD","LU2931357623.SGD","SG9999015978.USD","BK1509","LU0345770308.USD","LU1188198961.HKD","LU0588546209.SGD","LU2505996681.GBP","LU0683595622.HKD","LU2746668461.USD","LU0784639295.USD","LU0889565833.HKD","LU0823040885.USD","IE00BZ08YR35.GBP","LU0788109477.HKD","LU2213496289.HKD","LU2087589342.USD","3NVD.UK","LU2089985449.USD","LU2357125470.USD","LU0072462426.USD","AGOX","ILDR","LU0466842654.USD","LU1244550494.USD","LU1429558221.USD","TCHI","LU0048597586.USD","BK1191","LU0791591158.USD","LU0456827905.SGD","LU1196710195.USD","LU1232071149.USD","LU1400636657.SGD","SG9999002463.SGD","LU1226287792.SGD","LU1989764748.USD","LU0786609619.USD","LU1244550221.USD","SG9999014575.USD","ANV","CNEQ","LU0265550946.USD","LU0640476718.USD","LU1720051108.HKD","IE00BKDWB100.SGD","SG9999017495.SGD","LU0329678170.USD","NVD","CTIHY","LU2430703251.USD","LU1923623000.USD","BK4554","LU1629966141.USD","LU0472753341.HKD","LU0320765059.SGD","LU2746668974.SGD","LU0541502299.USD","LU0943347566.SGD","LU1951198990.SGD","LU2999663052.SGD","LU1880383366.USD","LU1674673691.USD","LU2433249047.HKD","LU0048388663.USD","IE00BMPRXR70.SGD","LU1992135399.USD","LU1770036033.HKD","LU2125154778.USD","LU1224709979.USD","IE00BFSS8Q28.SGD","LU1732800096.USD","IE00BZ08YS42.EUR","BK1589","LU2065171402.SGD","LU2463028550.USD","ESLG","LU2168564065.EUR","LU0516423174.USD","BK4587","LU1868837300.USD","LU2471134952.CNY","LU2077746001.SGD","LU0187121727.USD","LU0320764755.SGD","IE00B0169L03.USD","IE00B1BXHZ80.USD","LU2452424414.USD","LU2097344357.USD","LU0094547139.USD","NVC","LU0886674414.USD","IE00B1XK9C88.USD","LU1066053197.SGD","LU2498475776.HKD","IE00BYXW3230.USD","LU2552382215.SGD","LU0308772762.SGD","LU0196878994.USD","BK4579","SG9999014880.SGD","IE00B3M56506.USD","LU2152927971.USD","LU0310800379.SGD","HK0000288784.HKD","SG9999002828.SGD","LU1993786604.SGD","LU0819123356.HKD","CMAG","LU0957791311.USD","LU2237443978.SGD","LU1917777945.USD","HK0001040143.USD","LU0315179316.USD","HK0000304805.HKD","LU2083900584.USD","LU1439103000.SGD","BK1608","LU0823421416.USD","LU0633140560.USD","LU0633140727.USD","LU2237443622.USD","LU0878004406.USD","LU1979441026.SGD","LU2347655156.SGD","LU0348814723.USD","LU0823413587.USD","LU2462591350.SGD","LU0082616367.USD","LU0029874905.USD","LU0228367735.SGD","LU0289960550.SGD","IE00BQXX3C00.GBP","LU1035773651.USD","LU3102509885.SGD","BK4605","LU0345775950.USD","LU2279689827.SGD","BK4548","ODDS","LU2637965513.SGD","LU0011850046.USD","LU0634319403.HKD","LU2592432038.USD","LU1675838814.USD","LU0821914370.USD","LU2244417387.USD","LU0354030511.USD","LU0329678337.USD","LU0210526637.USD","IE00BPRC5H50.USD","LU0174119429.USD","LU2290526834.HKD","LU0011963245.USD","LU0856984785.SGD","LU0868494617.USD","LU2896262040.SGD","LU1934455277.USD","LFGY","LU1571399168.USD","SOXY","BK1502","LU0823397103.USD","LU2257852520.SGD","BK4608","LU1044876610.USD","LU1992135472.HKD","LU0289739343.SGD","IE00B5949003.HKD","LU0164865239.USD","LU0096364046.USD","LU0320764243.SGD","LU1770034418.SGD","LU2360032135.SGD","LU2063271972.USD","LU0957808578.USD","LU0348805143.USD","LU2097344431.USD","CHAT","LU1868836591.USD","SPTE","IE00BK4W5L77.USD","SG9999002562.SGD","LU0965508806.USD","LU2251237306.USD","BK4567","LU0516422952.EUR","LU1044875133.USD","CHPX","LU1226287875.USD","HK0000306701.USD","LU0642271901.SGD","LU2237443382.USD","LU0456846285.SGD","LU2065170008.USD","LU1366192091.USD","LU0831103253.SGD","LU1261432733.SGD","LU2054465674.USD","SG9999018857.SGD","IE00B031HY20.USD","LU2361044865.SGD","LU0326948709.USD","BK1517","LU0882747503.HKD","BK1591","LU0203347892.USD","BK1618","LU0029864427.USD","IE00BQXX3F31.USD","LU0211331839.USD","LU0054450605.USD","LU0106261372.USD","LU2236285917.USD","IE00B775H168.HKD","LU0173614495.USD","IE00BJTD4N35.SGD","XLK","JGRO","LU0528227936.USD","LU2237957811.SGD","LU0067412154.USD","SG9999014559.SGD","LU2487616109.SGD","IE00B3S45H60.SGD","IE00BF5LJ272.USD","LU0593848301.USD","LU1861558580.USD","LU0868486357.SGD","LU1196710864.SGD","IE00B19Z8W00.USD","IE0004091025.USD","09388","LU0106252389.USD","LU1974910355.USD","TYLG","BK4533","LU0077335932.USD","00013","LU1808992512.USD","LU2125909593.SGD","LU3063872942.SGD","LU1655091459.SGD","HTCD.SI","IE00BJJMRY28.SGD","LU0096362180.USD","LU0127658192.USD","ARTY","WISE","LU1048588211.SGD","LU2778985437.USD","LU0455707207.USD","LU1989772923.USD","IE00BK4W5M84.HKD","IE00B7KXQ091.USD","LU1712237335.SGD","IE00BZ1G4Q59.USD","LU1282651048.USD","IE0008368742.USD","LDEM","LU0081259029.USD","LU1733274473.HKD","LU1720050803.USD","IE0008368411.USD","LU0942090050.USD","LU2028103732.USD","LU0175139822.USD","LU0006306889.USD","LU0345769631.USD","LU1366333091.USD","BK1615","LU0501845795.SGD","LU0211328371.USD","LU1688375341.USD","LU2148510915.USD","LU2417539215.USD","LU0181495838.USD","SG9999002232.USD","HK0000304797.USD","SG9999004303.SGD","LU1810669033.SGD","LU1868837722.USD","LU2097828805.USD","LU0234572021.USD","LU0708994859.HKD","BK4612","LU0348735423.USD","BK1516","LU1725190679.HKD","LU0049112450.USD","LU0128525929.USD","LU2242650005.HKD","LU2456880835.USD","LU0276348264.USD","LU2087625088.SGD","LU0029875118.USD","SG9999000459.SGD","LU2168564222.USD","BK1588","IE00B5MMRT66.SGD","LU0964807845.USD","LU1066051498.USD","IE00BWXC8680.SGD","LU2097828474.EUR","LU1144417596.USD","LU2251237488.HKD","SG9999015341.SGD","IE00BSNM7G36.USD","LU0650527681.SGD","LU2237957902.USD","LU0545039389.USD","LU1670756490.USD","LU0143863784.USD","LU0261947096.USD","LU0823414551.USD","LU1366334651.USD","LU1066051811.HKD","LU2242649171.HKD","LU2108987350.USD","LU0323591593.USD","LU0700851271.USD","LU0348783662.USD","LU1868837565.USD","LU0097036916.USD","LU0577902538.SGD","TRFK","LU1642822529.SGD","LU1804176565.USD","NVDQ","SGXZ23171101.USD","TCEHY","LU1551013342.USD","SMHX","DIPS","BK4592","LU1721428933.USD","LU1211504680.USD","LU0820561909.HKD","LU1008478684.HKD","LU0823041008.USD","LU2362540622.SGD","BK4141","LU0509642566.USD","00425","SG9999001226.SGD","LU1807302812.USD","LU0414403682.SGD","LU0611395673.USD","LU1316542783.SGD","HCM","LU0726765562.USD","LU2106854487.HKD","LU0605514214.HKD","LU0384037296.USD","LU0256863811.USD","LU2430703095.HKD","LU0244354667.USD","LU0912757837.SGD","LU0084288322.USD","LU0267386448.USD","LU0898699433.AUD","LU0052750758.USD","LU2413666426.HKD","LU2750360641.GBP","THMR","LU0353189763.USD","LU2039709279.SGD","AIPI","LU0417517546.SGD","LU1153585028.USD","LU0985320562.USD","IE00B0JY6N72.USD","IE0034224299.USD","BK1526","LU0251144936.SGD","LU2293587155.HKD","LU2357305700.SGD","LU1674673428.USD","LU2247934214.USD","NVDB","LU1814569148.SGD","SG9999001093.SGD","BK1594","ESUM","IE0032834883.USD","LU2362541273.HKD","LU0577902611.USD","LU0348788117.USD","LU2177674079.SGD","BK1550","LU0107464264.USD","LU0577902454.USD","SG9999007991.SGD","LU0738912210.USD","LU0444971666.USD","IE00BN29S564.USD","IE00B775SV38.USD","LU2097828714.EUR","VT","BK4588","IE00BFSS7M15.SGD","LU0417516902.SGD","FDNI","LU1323998911.USD","LU0347712357.USD","LU1064131003.USD","LU1548497426.USD","SGXZ81514606.USD","LU1224444064.USD","TTEQ","LU0488056044.USD","SG9999015358.SGD","LU1868836914.USD","LU1935043452.HKD","LU0140636845.USD","LU0061477393.USD","HK0000352382.USD","IE000ITXATA3.USD","LU0287142896.SGD","LU0348723411.USD","BK1587","LU2264538146.SGD","IE00B8L5B284.USD","LU0594300419.USD","LU2756315318.SGD","HK0001040168.HKD","IE00BZ199S13.USD","LU0128522744.USD","LU0264606111.USD","LU0231483743.USD","LU0314109678.HKD","LU0238689110.USD","LU2008162690.USD","NVII","SGXZ99366536.SGD","LU2476274308.USD","LU1769817096.USD","IE00BKPKM429.USD","NVDO","SG9999002224.SGD","FDTX","LU0878005551.USD","LU1861220033.SGD","LU0225283273.USD","LU0203202063.USD","LU1037948897.HKD","METV","LU1145028129.USD","BK4532","IXN","LU0738911758.USD","LU1069347547.HKD","LU2543165471.USD","NVDW","LU0359202008.SGD","LU1242518857.USD","LU2125910849.SGD","LU0502904849.HKD","SGXZ80539844.SGD","LU0096374516.USD","LU0588545730.USD","LU0061474705.USD","LU1791710582.SGD","BK1554","TEK","IE0003U64NQ7.SGD","LU0588545490.SGD","IE000YTNTUN2.SGD","LU0149721374.USD","LU0469268626.HKD","VGT","LU0594300179.USD","LU0326950275.SGD","ESPO","LU2087621335.USD","LU0965509010.AUD","BK4549","LU1861127337.USD","IE000Q6AESB8.SGD","LU2279858448.HKD","IE0001KFT4U8.USD","LU0348783233.USD","IE00BMPRXQ63.HKD","LU0449515922.USD","BK4550","LU0234570918.USD","LU0390134368.USD","LU1282651121.HKD","LU1496350502.SGD","LU1568876335.HKD","LU1803068623.USD","LU1102505762.USD","LU0476273544.USD","LU2602419157.SGD","SOXQ","LU0132412106.USD","IE0003851619.USD","LU0170899867.USD","SGXZ51526630.SGD","LU1267930730.SGD","BK4581","LU1044874839.SGD","TTXU","LU2430703178.SGD","LU1914381329.SGD","LU0737861699.HKD","LU2317271919.USD","SG9999001051.SGD","LU0540923850.HKD","ROM","LU0128522157.USD","LU1226288253.USD","LU0577902298.EUR","NVDL","LU0211327993.USD","LU2125910500.SGD","LU2347655073.USD","HK0000532082.HKD","LU2023250330.USD","LU2168563687.JPY","LU1267930490.SGD","LU0577902371.SGD","LU1084165304.USD","LU0210527791.USD","IE00B5TLWC47.USD","LU0056508442.USD","LU0261950983.USD","LU0054237671.USD","IE0009G5SDU7.USD","LU1718418525.SGD","LU2361045086.USD","IE0003895053.USD","SG9999001689.USD","LU0672654166.SGD","LU0890818403.SGD","LU0345769128.USD","LU1935043536.SGD","SGXZ90724238.SGD","LU0316494557.USD","LU0353189680.USD","LU1645745479.HKD","LU0138981039.USD","LU1037948541.HKD","LU2413666699.HKD","LU3227948356.SGD","LU0228659784.USD","LU1226288170.HKD","LU2552382058.USD","TCHmain","LU0266013472.USD","LU1989764664.SGD","LU0608807433.USD","IE0005OL40V9.USD","SG9999014674.SGD","IE00B031J352.USD","LU0133085943.USD","LU0516422440.USD","LU0320764599.SGD","LU1923622614.USD","LU0873338254.USD","LU0823434740.USD","LU0553294199.USD","LU2462591277.SGD","ABFL","LU0589944569.HKD","LU0289961442.SGD","LU0307460666.USD","LU0588545904.SGD","LU2394011477.USD","LU1981816686.USD","SHOC","LU1568876251.USD","BK4543","LU0198837287.USD","LU0672654240.SGD","LU1642822792.SGD","LU2168564495.EUR","SNVDAmain","LU0828237940.HKD","LU1839511570.USD","HK0000320264.USD","IE0004445239.USD","SG9999000418.SGD","SOXX","LU1691799644.USD","NVDA","LU2065171311.SGD","LU2148611432.USD","LU1127390331.HKD","SOCL","LU0823426308.USD","LU1328277881.USD","SG9999015952.SGD","IE0009356076.USD","FFEM","LU0396098781.USD","LU2750360997.AUD","LU1629891620.HKD","LU1960683339.HKD","SNPE","LU1831875114.USD","BK1169","LU0572944931.SGD","LU2362541513.USD","LU0259732245.USD","AAXJ","LU0269904917.USD","LU0069063385.USD","BK4614","IE00B3SWFQ91.USD","LU2449936058.SGD","LU1046422090.SGD","LU2954938101.SGD","LU0561508036.HKD","NVDG","LU0675040207.SGD","LU2491050154.USD","LU1935042215.USD","HK0000914686.HKD","LU0823426480.USD","IE0009570106.USD","LU0049853897.USD","LU2272731600.USD","LU0607220059.USD","BK4534","LU0310799852.SGD","LU0256863902.USD","LU1244550577.SGD","LU0348784397.USD","LU1115378108.SGD","SG9999015945.SGD","LU0158827781.USD","BK1531","LU1280957306.USD","LU0061474960.USD","HK0000914660.USD","LU0871576103.HKD","LU2023250504.SGD","IE000W1ABFV2.USD","LU2023251221.USD","LU2111349929.HKD","LU2322448791.USD","IE00BZ08YT58.USD","LU2051468812.USD","HK0000288743.USD","LU2237443549.SGD","LU1815333072.USD","IE0008369823.USD","LU1551013425.SGD","LU1733274390.USD","LU2461242641.AUD","LU0456842615.SGD","LU2047632596.USD","IE00BDCRKT87.USD","BK1586","LU2552382132.HKD","NVDU","BK4527","LU0039217434.USD","LU0787776722.HKD","LU0823414478.USD","LU0149534421.HKD","LU0868494708.USD","BK4503","LU0965509283.SGD","LU1868837136.USD","LU1328615791.USD","LU2092627202.USD","IE0004445015.USD","CXSE","LU1951186391.HKD","LU0795875169.SGD","SNVD.UK","LU2211815571.USD","BK1610","LU1152091168.USD","LU0820562030.AUD","LU2265009873.SGD","LU2279701549.SGD","LU2458330243.SGD","LU1282649067.USD","LU2097828557.USD","BK1144","CLSE","LU1989772840.SGD","LU0862451753.SGD","LU0124676726.USD","LU1880398471.USD","LU0880133367.SGD","LU0823039010.USD","LU1791710400.SGD","LU1171460220.USD","LU1226288097.SGD","LU2272731865.HKD","LU1439102457.SGD","LU2360107168.USD","LU2471134796.USD","LU1323610961.USD","LU1861559042.SGD","KWEB","JADE","LU0323240290.USD","LU0251132253.USD","LU0661504455.SGD","SG9999018865.SGD","NVDS.UK","LU0719512351.SGD","LU1196710351.USD","LU2326559502.SGD","LU0417516571.SGD","LU0572939691.SGD","LU1035775433.USD","LU1719994722.HKD","IE00BKVL7J92.USD","NVD3.UK","LU0708995401.HKD","LU0823038988.USD","LU2100268510.USD","SG9999014898.SGD","LU0541501648.USD","LU2473716301.USD","LU0345770993.USD","LU1496350171.SGD","SG9999000327.SGD","LU0724617625.USD","LU2133065610.SGD","USXF","IE00BQXX3D17.EUR","LU0949170772.SGD","LU1734074674.USD","IE0032431581.USD","IE00B8HQ1Z84.USD","LU2294711473.HKD","LU0203345920.USD","LU0348827113.USD","LU0689626769.HKD","IE00B031HW06.USD","LU0057025933.USD","LU0143863198.USD","LU0882574139.USD","NVDX","LU0117841782.USD","LU1481107354.HKD","HK0000819398.USD","LU0323239441.USD","LU0865486749.SGD","LU1435385759.SGD","USD","LU0048580855.USD","LU1732799900.SGD","LU0345768740.USD","LU1066051225.USD","LU2125909916.SGD","LU1769817179.HKD","LU0791590937.USD","LU0965509101.SGD","LU0106959298.USD","LU1699723380.USD","LU2237443895.HKD","LU0043850808.USD","SG9999001903.USD","IE00BD6J9T35.USD","LU0516423091.SGD","LU1119994496.HKD","LU0109392836.USD","LU0543330566.HKD","LU0348816934.USD","LU1003077747.HKD","IE00B97KM107.HKD","LU1794554557.SGD","LU1935042991.SGD","LU1935042488.USD","LU0048584097.USD","00966","BK1184","2NVD.UK","LU0499858438.USD","LU0511384066.AUD","LU0708995153.HKD","LU0823421333.USD","HK0000151867.HKD","LU2381873111.SGD","LU1861215975.USD","LU0918141887.USD","LU2399975544.HKD","LU0499858602.USD","LU1880398554.USD","LU2125909247.SGD","BK4551","LU1504937902.USD","BK4585","LU1868838027.USD","LU0079474960.USD","LU0080751232.USD","LU0274383776.USD","LU1623119135.USD","09788","LU2322448957.HKD","LU1251922891.USD","LU2125154935.USD","LU2191332357.HKD","LU1048484197.HKD","LU1961090484.USD","LU0047713382.USD","LU0516422366.SGD","FAI","LU0823397285.USD","SG9999014914.USD","LU1023057109.AUD","AIFD","LU0143551892.USD","LU0165289439.USD","LU0683600562.USD","LU0441854154.USD","LU2097828631.EUR","LU2089284900.SGD","IE00B29SXG58.USD","LU0345768153.USD","LU0531971595.HKD","LU0254981946.USD","LU0163747925.USD","LU2065169927.USD","LU1956131251.USD","LU1934455863.HKD","EEMX","SG9999014906.USD","LU0823413660.USD","IE00BGV7N243.SGD","LU1400636574.HKD","IE00BJTD4V19.USD","LU1064130708.USD","LU0117844026.USD","LU2491049909.HKD","BK4598","LU1883866441.USD","LU2361044949.HKD","LU0215105999.USD","LU0359201612.USD","LU1803068979.SGD","EMC","LU0417516738.SGD","LU0737861772.HKD","LU0070217475.USD","LU1069344957.HKD","LU1868836757.USD","SG9999015986.USD","SG9999013353.USD","LU2756315664.SGD","IE00B543WZ88.USD","LU1400636491.USD","LU0164872284.USD","LU0203201768.USD","LU0820561818.USD","NVDY","LU1813983027.USD","HK0000352291.HKD","LU1105468828.SGD","LU0345776255.USD","LU0265550359.USD","IE00B0169N27.USD","LU0370786039.SGD","LU1152091754.HKD","LU2420271590.USD","IE00B4JS1V06.HKD","LU0651946864.USD","IE00B19Z8X17.USD","LU2092937148.SGD","IE00BHPRN162.USD","LU0359201885.HKD","BIDD","LU1267930573.SGD","LU0828237510.HKD","LU2471134879.HKD","HK0000320223.HKD","IE00BMPRXN33.USD","SG9999004220.SGD","07788","LU0708995583.HKD","IE0031814852.USD","03800","LU2237443465.HKD","LU2242644610.SGD","BKF","LU1852331112.SGD","IE00B19Z9505.USD","IE000KEQY171.SGD","LU0211977185.USD","BK1095","LU2237438978.USD","SG9999001424.SGD","IE00BJJMRX11.SGD","LU0315178854.USD","LU0229945570.USD","LU1778281490.HKD","LU2125909759.SGD","JEMA","LU0862451837.USD","LU0072913022.USD","LU2458330169.SGD","LU0572940350.SGD","LU0072462343.USD","LU0235996351.USD","LU1935043023.USD","NVIW.SI","LU1983260115.SGD","NULC","BK4529","LU0689472784.USD","LU2168564149.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122126542","title":"和黄医药公布9月股份变动月报表,股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1122126542","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1122126542?lang=zh_cn&edition=full","pubTime":"2026-10-02 16:49","pubTimestamp":1790930951,"startTime":"0","endTime":"0","summary":"和黄医药于2026年10月2日提交截至2026年9月30日的股份变动月报表。报告显示,公司本月股本无新增发行或回购活动,总股本保持不变。根据公告,截至本报告期末,公司法定/注册股本维持在1,500,000,000股,面值0.1美元,法定/注册股本总额为150,000,000美元。截至9月底,公司确认已持续满足香港联交所关于公众持股量的相关要求。本月股本总数保持在872,335,120股未发生变动。该月报由非执行董事兼公司秘书施熙德签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00013"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672752719","title":"和黄医药(00013):从跟随板块到跑赢板块,基本面确认后何时开启新一轮行情?","url":"https://stock-news.laohu8.com/highlight/detail?id=2672752719","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2672752719?lang=zh_cn&edition=full","pubTime":"2026-10-01 20:33","pubTimestamp":1790857981,"startTime":"0","endTime":"0","summary":"以8月26日盘中高点4018.32点计算,板块区间最大涨幅已达到36.77%。但在6月22日后,和黄医药股价开始出现一波反弹,这一行情表现也与同期板块走势高度相关。而这也成为和黄医药股价开始低位修复的主要原因之一。7月30日,和黄医药正式披露了其2026年上半年财报。但这并不意味着和黄医药已步入新的主升浪行情。而能否在后续收盘放量站上前高股价,或成为投资者技术面研判和黄医药是否有望启动新一轮主升浪行情的重要量价指标。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1503120.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","BK1587","00013","BK1588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671884917","title":"利弗莫尔中概股龙头指数盘初微涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2671884917","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671884917?lang=zh_cn&edition=full","pubTime":"2026-09-30 21:35","pubTimestamp":1790775300,"startTime":"0","endTime":"0","summary":"每经AI快讯,9月30日,利弗莫尔中概股龙头指数盘初上涨0.6%,报9229.35点。成分股中,南茂涨5.87%,贝壳涨3.07%,理想汽车涨2.32%,万国数据涨2.29%,和黄医药涨2.12%。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2026-09-30/doc-initrmyr6760054.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-09-30/doc-initrmyr6760054.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4531","BEKE","BK4548","LU0359202008.SGD","LU0173614495.USD","BK4588","BK4563","LU1188198961.HKD","EVS.SI","LU0463099449.HKD","BK4116","BK4526","BK4504","BK4607","LU1831875114.USD","LU0651946864.USD","BK1588","00013","LU0287142896.SGD","BK4505","BK4503","LU0326950275.SGD","BK4614","HCM","BK4529","09698","LU1023057109.AUD","LU0651947912.USD","BK4079","LU0359201885.HKD","LU0359201612.USD","BK4551","GDS","LU1051768304.USD","LU1515016050.SGD","02015","BK1587","02423","LI","BK4585","LU0244354667.USD","BK4509","LU1688375341.USD","LU1051769294.HKD","BK4099","BK4555","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671224170","title":"港股异动 | 和黄医药(00013)涨超3% 宣布向FDA提交沃瑞沙®联合泰瑞沙®联合疗法的新药上市申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2671224170","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671224170?lang=zh_cn&edition=full","pubTime":"2026-09-30 10:50","pubTimestamp":1790736612,"startTime":"0","endTime":"0","summary":"消息面上,9月29日,和黄医药发布公告,阿斯利康已向美国食品药品监督管理局提交沃瑞沙 和泰瑞沙 的联合疗法的新药上市申请,用于治疗接受一种表皮生长因子受体酪氨酸激酶抑制剂治疗期间或之后出现疾病进展的伴有MET过表达或扩增的局部晚期或转移性非小细胞肺癌患者。SAFFRON全球III期研究的数据支持了该项新药上市申请。据悉,沃瑞沙由阿斯利康与和黄医药共同开发,并由阿斯利康商业化。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1502493.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","LABU","BK1587","BK4588","BK1588","KCAI","IPOS","BK1191","00013","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106699126","title":"和黄医药(00013)携手阿斯利康向FDA递交沃瑞沙®/泰瑞沙®联合疗法NDA","url":"https://stock-news.laohu8.com/highlight/detail?id=1106699126","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1106699126?lang=zh_cn&edition=full","pubTime":"2026-09-29 08:10","pubTimestamp":1790640650,"startTime":"0","endTime":"0","summary":"2026年9月29日,和黄医药(中国)有限公司公告称,其合作伙伴阿斯利康已向美国食品药品监督管理局提交沃瑞沙联合泰瑞沙的新药上市申请,拟用于治疗在表皮生长因子受体酪氨酸激酶抑制剂治疗期间或之后出现疾病进展、且伴有MET过表达或扩增的局部晚期或转移性非小细胞肺癌患者。该疗法为全口服、无化疗方案,定位于满足MET驱动耐药患者的未被满足需求。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00013"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671668622","title":"和黄医药(00013)宣布提交沃瑞沙® (ORPATHYS®) 联合泰瑞沙® (TAGRISSO®) 用于治疗MET驱动的EGFR突变肺癌的美国新药上市申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2671668622","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671668622?lang=zh_cn&edition=full","pubTime":"2026-09-29 08:03","pubTimestamp":1790640236,"startTime":"0","endTime":"0","summary":"智通财经APP讯,和黄医药 公布,阿斯利康已向美国食品药品监督管理局提交沃瑞沙 和泰瑞沙 的联合疗法的新药上市申请,用于治疗接受一种表皮生长因子受体酪氨酸激酶抑制剂治疗期间或之后出现疾病进展的伴有MET过表达或扩增的局部晚期或转移性非小细胞肺癌患者。SAFFRON全球III期研究的数据支持了该项新药上市申请。然而 MET过表达或扩增是导致第三代EGFR TKI治疗后耐药的最常见的机制之一。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1501807.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IPOS","BK1588","00013","BK1587","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669432191","title":"和黄医药(00013.HK):将于2026年欧洲肿瘤内科学会 (ESMO) 年会公布数项研究临床数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2669432191","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669432191?lang=zh_cn&edition=full","pubTime":"2026-09-24 08:09","pubTimestamp":1790208598,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1588","BK1587","BK1191","00013"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669711744","title":"3年赚了40多亿的和黄医药,李嘉诚才不肯卖","url":"https://stock-news.laohu8.com/highlight/detail?id=2669711744","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669711744?lang=zh_cn&edition=full","pubTime":"2026-09-22 16:48","pubTimestamp":1790066930,"startTime":"0","endTime":"0","summary":"算上资产处置的一次性收益,和黄医药近三年累计净利润已经超过40亿元。本次重磅BD,有望抬升和黄医药的平台估值与行业地位。但过去几年,作为现金奶牛的中药业务被剥离,和黄医药失去了这一稳定的利润缓冲垫,进一步导致整体经营波动被放大。此前和黄医药转让上海和黄药业大部分股权,完成现金牛出清。对比来看,押注创新药的和黄医药,不属于这类存量资产。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1789038618464719258","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["00013","BK1588","BK1521","BK1587","LU2148510915.USD","LU1064130708.USD","LU1571399168.USD","BK1601","IE0032431581.USD","LU1048588211.SGD","BK1500","BK1230","LU1064131003.USD","BK1569","BK1191","LU0211977185.USD","LU0072462343.USD","00001"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668195427","title":"港股异动 | 和黄医药(00013)尾盘涨超3% ATTC授权GSK 机构指公司出海路径清晰","url":"https://stock-news.laohu8.com/highlight/detail?id=2668195427","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668195427?lang=zh_cn&edition=full","pubTime":"2026-09-17 15:26","pubTimestamp":1789629963,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,和黄医药尾盘涨超3%。截至发稿,涨2.72%,报21.9港元,成交额9056.96万港元。消息面上,9月3日,公司公告与GSK就HMPL-A830达成独家许可协议,GSK以首付款/里程碑1.1/11.85亿美元获海外权益。华福证券表示,看好HMPL-A830有望以差异化机制切入CRC的KRAS突变未满足市场,建议重点跟踪I期数据读出。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1497326.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1587","00013","KCAI","VXUS","BK4588","BK1191","BK4585","BK1588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665342123","title":"中金:维持和黄医药(00013)“跑赢行业”评级 目标价升至28港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2665342123","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665342123?lang=zh_cn&edition=full","pubTime":"2026-09-08 13:37","pubTimestamp":1788845857,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,中金发布研报称,维持和黄医药“跑赢行业”评级,上调目标价7.7%至28港元。考虑到本次交易于今年达成,该行调整2026年及2027年确认收入节奏,上调2026年净利润预测41%至7,807万美元,下调2027年净利润预测25%至6,638万美元。和黄医药近日公告与葛兰素史克达成独家开发和许可协议,将HMPL-A830除中国以外的全球开发和商业化权益授予GSK。该行认为GSK是有力合作伙伴,并指ATTC平台获跨国药企背书,除HMPL-A830外,PI3K/PIKK系列管线亦具备看点。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1493228.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["EWH","00013"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665062393","title":"一个还没进临床的分子,凭什么卖出12.95亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2665062393","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665062393?lang=zh_cn&edition=full","pubTime":"2026-09-07 10:08","pubTimestamp":1788746914,"startTime":"0","endTime":"0","summary":"对一款尚未进入人体临床试验的资产而言,1.1亿美元的首付款属于明显偏高的定价。2023年,和黄医药将已在中国获批上市的呋喹替尼授权给武田制药:总额11.3亿美元,首付款4亿美元。那是\"成熟产品出海\"的典范,一个经过临床验证、获批上市的分子,换取全球市场权益。HMPL-A830尚未启动I期临床,和黄医药卖的是一个\"概念验证前\"的平台资产,而12.95亿美元的总交易额,已经超过了呋喹替尼的11.3亿美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1788491648644278418","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["KURE","BK4231","BK1588","BK4080","NETL","BK1587","ADC","BK1191","00013"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664330739","title":"总额可达12.95亿美元,和黄医药BD落地,管理层回应市场疑虑:借助合作加速开发,但不会调整整体战略","url":"https://stock-news.laohu8.com/highlight/detail?id=2664330739","media":"每日经济新闻","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664330739?lang=zh_cn&edition=full","pubTime":"2026-09-04 22:40","pubTimestamp":1788532800,"startTime":"0","endTime":"0","summary":"“HMPL-A830是我们创新有效载荷平台下的第三款候选药物,也是继前两款候选药物进入临床开发后,我们平台旗下首个授权予全球合作伙伴的候选药物”,和黄医药管理层这样定义9月3日上午官宣的合作交易。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609043865728649.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609043865728649.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1587","BK1588","BK1191","00013"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664384254","title":"花旗:上调和黄医药(00013)目标价至39港元 维持“买入/高风险”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2664384254","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664384254?lang=zh_cn&edition=full","pubTime":"2026-09-04 14:58","pubTimestamp":1788505097,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,花旗发布研报称,将和黄医药(00013)目标价由36港元上调至39港元,维持“买入/高风险”评级。该行同时上调公司2026至2028年肿瘤/免疫业务收入预测27%、26%及14%,每股盈利预测上调至0.08、0.09及0.13美元。和黄医药与GSK就HMPL-A830(KRAS-EGFR ATTC)达成授权协议。花旗认为,GSK的认可验证了ATTC平台概念,且交易较该行预期更早达成。另外,花旗预计HMPL-A251及HMPL-A580于今年底至明年初首次患者给药,届时更多人体数据将进一步验证ATTC平台。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1492006.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["EWH","00013"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664389940","title":"大行评级丨里昂:维持和黄医药“跑赢大市”评级,ATTC平台获跨国药企认可","url":"https://stock-news.laohu8.com/highlight/detail?id=2664389940","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664389940?lang=zh_cn&edition=full","pubTime":"2026-09-04 13:18","pubTimestamp":1788499093,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["00013","BK1191","BK1588","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664385549","title":"大行评级丨大和:上调和黄医药目标价至28.5港元,评级一举升至“买入”","url":"https://stock-news.laohu8.com/highlight/detail?id=2664385549","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664385549?lang=zh_cn&edition=full","pubTime":"2026-09-04 10:53","pubTimestamp":1788490409,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["00013","EWH","BK1191","BK1588","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664388725","title":"港股异动 | 和黄医药(00013.HK)再涨超6% 与GSK达成12.95亿美元合作 ATTC平台全球价值得到验证","url":"https://stock-news.laohu8.com/highlight/detail?id=2664388725","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664388725?lang=zh_cn&edition=full","pubTime":"2026-09-04 09:36","pubTimestamp":1788485764,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["00013","BK1587","BK1588","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107128857","title":"异动解读|和黄医药盘中上涨5.3%,与葛兰素史克达成最高12.95亿美元授权合作提振延续","url":"https://stock-news.laohu8.com/highlight/detail?id=1107128857","media":"行情直击","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1107128857?lang=zh_cn&edition=full","pubTime":"2026-09-04 09:35","pubTimestamp":1788485702,"startTime":"0","endTime":"0","summary":"9月4日,和黄医药盘中上涨5.3%,报23.26港元,成交额1.14亿港元,延续前一交易日强势表现。协议包含1.1亿美元首付款,叠加开发、注册及商业化里程碑付款,总额最高可达12.95亿美元,另含基于净销售额的特许权使用费。该消息于前一交易日已推动股价大涨逾16%,今日涨势为市场对这一重磅授权合作的情绪延续。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"和黄医药强势上涨,与葛兰素史克达成重磅授权合作","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00013"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664238859","title":"【券商聚焦】交银国际:医药行业收入稳健增长 多重利好推动盈利表现显著改善","url":"https://stock-news.laohu8.com/highlight/detail?id=2664238859","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664238859?lang=zh_cn&edition=full","pubTime":"2026-09-04 09:00","pubTimestamp":1788483634,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际表示,1H26港股/A股医药行业整体收入增长4.7%/3.2%。创新药产业链增速领跑行业,服务板块复苏:1)港股/A股CXO收入整体增长29.2%/25.3%,(扣非)净利润增长23.4%/67.6%,在各子板块中增速最快,行业整体景气度和订单需求处于高位。2)核心成药板块收入增长17.8%/3.4%、利润增长62.7%/35.0%。其中生物药增速远超化药,在板块收入中的占比也进一步提升。3)医院、器械、诊断、疫苗等板块业绩有复苏趋势。","market":"us","thumbnail":"https://static.szfiu.com/news/20250109/ODJmOWY1ZDhkZDY4MmEzZDMyMTcwNTE1ODgyMzc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/ODJmOWY1ZDhkZDY4MmEzZDMyMTcwNTE1ODgyMzc=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1990646","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06078","LU1251922891.USD","LU0856984785.SGD","SG9999004220.SGD","LU1152091168.USD","01093","02268","06821","06160","BK1515","03759","00013","01548","06996","LU0039217434.USD","LU0315179316.USD","01952","02162","HK0000306685.HKD","LU0307460666.USD","02096","KURE","01530","03692","LU0348783233.USD","BK1209","01177","LU1242518857.USD","LU0327786744.USD","03329","KCE","01801","09966","01276","BK1161","IE00B543WZ88.USD","IE00B5MMRT66.SGD","LU1880383366.USD","IE00B0JY6N72.USD","HK0000320264.USD","09926","06990","02269","BK1589","LU0588546209.SGD","01951","02596","LU2543165471.USD","02273","09996"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.hutch-med.com","stockEarnings":[{"period":"1week","weight":-0.0338},{"period":"1month","weight":-0.0018},{"period":"3month","weight":0.2276},{"period":"6month","weight":-0.0757},{"period":"1year","weight":-0.1441},{"period":"ytd","weight":0.0543}],"compareEarnings":[{"period":"1week","weight":0.01},{"period":"1month","weight":-0.0421},{"period":"3month","weight":0.0015},{"period":"6month","weight":-0.065},{"period":"1year","weight":-0.095},{"period":"ytd","weight":-0.0554}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"和黄医药(中国)有限公司是一间主要从事制造及销售药物的投资控股公司。该公司主要通过两个分部运营业务。肿瘤免疫业务分部从事发现、开发和商业化用于治疗癌症和免疫性疾病的靶向疗法和免疫疗法。其中研发包括涵盖药物发现、开发、生产及监管职能的研发活动,上市产品包括通过研发活动开发的药物的已开具发票的销售、推广、生产及分销。其他业务分部从事其他商业化业务,包括其他处方药物及保健品的销售、推广、生产及分销。","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.066388},{"month":2,"riseRate":0.6,"avgChangeRate":0.075835},{"month":3,"riseRate":0.2,"avgChangeRate":-0.093928},{"month":4,"riseRate":0.4,"avgChangeRate":0.010831},{"month":5,"riseRate":0,"avgChangeRate":-0.149846},{"month":6,"riseRate":0.4,"avgChangeRate":0.004362},{"month":7,"riseRate":1,"avgChangeRate":0.132805},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.047962},{"month":9,"riseRate":0.666667,"avgChangeRate":0.027356},{"month":10,"riseRate":0.166667,"avgChangeRate":-0.042973},{"month":11,"riseRate":0.4,"avgChangeRate":0.13917},{"month":12,"riseRate":0.4,"avgChangeRate":-0.030017}],"exchange":"SEHK","name":"和黄医药","nameEN":"HUTCHMED"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"和黄医药(00013)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供和黄医药(00013)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"和黄医药,00013,和黄医药股票,和黄医药股票老虎,和黄医药股票老虎国际,和黄医药行情,和黄医药股票行情,和黄医药股价,和黄医药股市,和黄医药股票价格,和黄医药股票交易,和黄医药股票购买,和黄医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"和黄医药(00013)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供和黄医药(00013)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}